Inhibrx Biosciences
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Inhibrx Biosciences's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 17% to $1,800,000. Profit margin reached -13409%. Total operating expenses were $219,830,000.
Profit Margin
| 2017 | 7.95M | -19.44M | -244.55% |
|---|---|---|---|
| 2018 | 7.5M | -31.16M | -415.51% |
| 2019 | 9.09M | -51.4M | -565.27% |
| 2020 | 12.80M | -75.63M | -590.54% |
| 2021 | 7.12M | -81.76M | -1147.62% |
| 2022 | 2.17M | -145.22M | -6667.86% |
| 2023 | 1.8M | -241.36M | -13408.94% |
INBX Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 1.8M | 2.17M | 7.12M | 12.80M | 9.09M | 7.5M | 7.95M |
Cost of revenue | 1.19M | 2.84M | 2.68M | 73.49M | 47.90M | 33.45M | 25.51M |
Gross profit | 609K | -668K | 4.43M | -60.68M | -38.81M | -25.95M | -17.56M |
Operating exp. | |||||||
Research and development | 191.64M | 110.18M | 71.44M | 73.49M | 47.90M | 33.45M | 25.51M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 219.83M | 131.29M | 83.68M | 80.25M | 52.80M | 37.01M | 27.67M |
Operating income | -219.22M | -129.11M | -76.56M | -67.44M | -43.71M | -29.51M | -19.72M |
Other income (expenses), net | -20.50M | -16.10M | -5.20M | -8.19M | -6.78M | 68K | -2.10M |
Income before tax | -239.72M | -145.22M | -81.76M | -75.63M | -50.50M | -30.92M | -21.83M |
Income tax expense | 3K | 3K | 2K | 3K | 898K | 96K | 250K |
Net income | -241.36M | -145.22M | -81.76M | -75.63M | -51.4M | -31.16M | -19.44M |
Earnings per share | |||||||
Basic EPS | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 |
Diluted EPS | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 |
| Data source | Data source | Data source | Data source |